Treatment of alzheimer's disease
OwnerIsaac Eliazinventor
Life of this patent
Estimating the term…
Abstract
Patients suffering from, or at risk of developing the symptoms of, Alzheimer's disease and related neuroinflammatory-based diseases, are treated by apheresis to selectively withdrawal Galectin-3 from the patient's body. A reduction in the circulating level of gal-3 of the patient of at least 30% of the patient's pre-treatment galectin-3 level should be sufficient to reduce AD symptoms, and/or inhibit AD progression. A greater withdrawal, up to at least 20%, has greater impact. Selective withdrawal of Galectin-3 may be coupled with the administration of MCP to further slow the progress of, and/or reverse, AD symptoms.
Claims8
A method of treating Alzheimer's disease in humans, comprising:
- A) Identifying a human patient in need of treatment to address Alzheimer's disease, and
- B) Treating said identified patient to selectively withdraw galectin-3 through apheresis so as to lower the patient's galectin-3 level by at least 30%
A method of treating a human patient suffering from disease mediated by neuroinflammation including any one of frontotemporal dementia, progressive supranuclear palsy, amyotrophic lateral sclerosis, corticobasal degeneration, and Parkinson's disease, comprising:
- A) Identifying said patient and
- B) Treating said identified patient to selectively withdraw galectin-3 through apheresis so as to lower the patient's overall galectin-3 level by at least 30%.
Dependencies are inferred from the claim text.